Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation
Author(s) -
Catherine Cordonnier,
Myriam Labopin,
Virginie Chesnel,
Patricia Ribaud,
Rafael de la Cámara,
Rodrigo Martino,
Andrew J. Ullmann,
T Parkkali,
Anna Locasciulli,
Karima Yakouben,
Karlis Pauksens,
Hermann Einsele,
Dietger Niederwieser,
Jane F. Apperley,
Per Ljungman
Publication year - 2009
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/598324
Subject(s) - medicine , transplantation , pneumococcal conjugate vaccine , vaccination , pneumococcal polysaccharide vaccine , randomized controlled trial , surgery , streptococcus pneumoniae , immunology , pneumococcal disease , antibiotics , microbiology and biotechnology , biology
Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after transplantation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom